Lobby Wrap: Pro-psilocybin group enlists By Charlie Pinkerton. Published on Mar 1, 2021 11:43am The West Block of the Parliament buildings (Jolson Lim/iPolitics)
Last week,
Therapsil, a non-profit that seeks to promote access to psilocybin therapy, saw a board of directors’ member join the Lobby Registry. It’s looking to promote patient-centred psilocybin research in Canada, and help patients and doctors access psilocybin through special regulations.
Kitchener-based cybersecurity company
Palitronica Inc was the only client organization with more than two registrations. Four other companies had two apiece:
Staples Canada ULC,
Cape Breton University, and tech company
Benchmark Corp.
Global Public Affairs was the most active lobbying firm, racking up six registrations this week; CFN Consultants had the second-most with five; Capital Hill Group and Summa Strategies each had four; StrategyCorp Inc. had three registrations; and PAA Public Affairs Advisors, Im
InterVivo Solutions Issued Institutional Cannabis Research License by Health Canada
Toronto, Ontario (Newsfile Corp. - February 4, 2021) - InterVivo Solutions Inc. ( InterVivo or the Company ), a leading Canadian contract research organization providing preclinical
in vivo research services that enable the pharmaceutical and nutraceutical industries to develop new products and therapies for neuropsychiatric and neurological diseases, is pleased to announce that it has been issued an Institution-wide Research License from Health Canada under the Cannabis Act and Cannabis Regulations.
The Institution-wide Research License (IRL) enables InterVivo to conduct multiple studies across all departments at its research facility without the need to apply for study-specific research licenses. Essentially, InterVivo is now granted broad approval to research and develop all cannabis-based products across all of its translational drug discovery services. InterVivo s clients will benefit with